Millennium Food-Tech in 2025: The Book Value Is Still There, but Getting to It Still Runs Through Funding

Getting To Know The Company

Millennium Food-Tech can look, at first glance, like just another tiny listed food-tech story with a big dream and a small market value. That is too shallow a read. In practice, this is a public investment partnership, not an operating product company. It does not consolidate its portfolio companies. It measures them at fair value through profit and loss. That means the economics of the listed vehicle are driven less by its own operating revenue and more by three other things: the quality of the private holdings, the ability to finance them until they mature, and the ability to turn book value into value that actually reaches unitholders.

What is working now? The three main holdings still carry real weight. Tipa, TripleW and Pitolon together account for NIS 48.1 million, or about 84.7% of the private portfolio's fair value at the end of 2025. Pitolon received FDA approval for its first product after the balance sheet date. TripleW continues to show industrial progress and meaningful grant support. Tipa keeps expanding its product set and completed strategic moves in Europe. At the same time, the partnership has already completed a rights offering in early 2026, so it is not facing an immediate cash wall right now.

But the picture is still not clean. The active bottleneck is access to value. At year-end 2025, equity stood at NIS 64.1 million, non-traded investments at NIS 56.8 million, and the market value in early April 2026 was only about NIS 16.3 million. In other words, the market is valuing the partnership at roughly one quarter of equity. That does not automatically mean the book value is fictitious. It mostly means public investors are not convinced Millennium can get there without more time, more funding and more dilution.

That is also a real actionability constraint, not a theoretical one. On the last trading day in the market snapshot, turnover was only about NIS 29 thousand. In a stock like this, even a successful raise is not just a question of whether capital is available, but at what equity price it can be raised.

The Real Value Map

That is the key number. The broad diversification story has already eroded. Several older holdings have already been written down to zero, including Ag-Ann-Ap, Nuko, Yofix and Green Klia. Aleph Farms is down to only NIS 849 thousand. So anyone still reading Millennium as a broadly diversified vehicle is missing what the annual package now says in practice: this is no longer a partnership of ten similarly relevant holdings. It has become a concentrated bet on a small number of names, above all on the three companies the partnership itself defines as material.

Events And Triggers

The core insight here is that early 2026 already changed the picture, but did not solve it. The partnership bought more time, got a positive catalyst in Pitolon, and received confirmation that the portfolio is still alive. It still has not received proof that the value is truly on its way out.

The first trigger: the rights offering was completed after the balance sheet date. In February and March 2026 the partnership issued 7,621,537 participation units at NIS 0.9 per unit and 7,621,537 warrants for no additional consideration, with a NIS 1 exercise price until September 3, 2026. Gross proceeds came to about NIS 6.859 million. This matters because it shows Millennium can still access the market. It also sharpens the point that Millennium still needs the market. Both things are true at the same time.

The second trigger: Pitolon moved from being mostly a story holding to a holding with a measurable regulatory event. After the balance sheet date, its first product, Beetroot Red, received FDA approval for marketing in the United States, subject to the public-comment period, and the company said it was preparing supply through European contract manufacturing lines. At the same time, a February 2026 immediate report said Pitolon was examining a significant strategic-investor raise at a valuation far above the last funding rounds. There is no certainty the transaction will close, but this is the sharpest external catalyst in the evidence set.

The third trigger: TripleW keeps generating a sense of progress, but it still requires capital. In December 2025 Millennium invested another $150 thousand through a convertible instrument that carries 8% interest and is repayable only through conversion into shares. That helps the portfolio company, but it also reminds investors who is still funding whom.

The fourth trigger: Tipa completed two strategic moves in 2025, following its earlier acquisition of full control in Dutch company B4P, and then taking full control of Sealpap in the fourth quarter. Tipa also launched a new set of high-barrier and paper-based products. That supports a broader commercialization narrative, but it still does not give the public reader a full cash-disclosure picture.

Efficiency, Profitability And Competition

The reported numbers can mislead if they are read like those of an operating company. Net loss in 2025 was NIS 15.2 million, a sharp improvement from a NIS 39.9 million loss in 2024. Anyone who stops there misses the point. The improvement came mainly because fair-value losses on investments fell to NIS 11.8 million from NIS 36.6 million a year earlier. That does not mean the partnership built a stable profit engine. It means the portfolio took less accounting damage in 2025.

The listed vehicle itself barely has a recurring income layer. Advisory revenue from portfolio companies was only NIS 29 thousand. Total revenue was NIS 510 thousand. Against that, general and administrative expenses were NIS 3.107 million, and management and incentive-fee expense to the general partner was NIS 740 thousand. This is not a public platform that funds itself from operations. It is a holding platform waiting for its assets to mature.

Earnings Quality

What matters is that not all of the 2025 accounting hit reflects a broad deterioration in the underlying holdings. In Pitolon, fair value remained at $3.799 million in both 2024 and 2025, and the NIS 1.736 million hit came from foreign-exchange translation. In TripleW, the economic review included in the annual package said the legacy holding remained at $4.255 million, and the increase to $4.405 million simply reflects the extra $150 thousand Millennium invested. Again, the P&L hit is mostly currency translation. In Tipa, fair value in dollars actually rose modestly, from $6.775 million to $6.864 million, but the shekel value still fell because FX expense was larger than the positive fair-value adjustment.

That matters because it separates two very different debates. One debate says the portfolio collapsed. That is not what the annual package shows. The other debate says the value is still soft, private, and assumption-driven, and Millennium still does not know how to turn it into cash. That is the more accurate debate.

The Quality Of The Main Assets

Tipa is the best example of the gap between book value and accessible value. In the portfolio-company description, Millennium says Tipa had no going-concern note in its latest audited 2024 financials, had no loans other than supplier credit, and estimated it would not require additional investment during the coming year. But the public description also says Tipa refused to disclose its burn rate and cash balance on the grounds that they are commercially sensitive. So the public reader does not get full comfort from the business description itself. That comfort comes only through the attached valuation review, where management told the valuer that Tipa had about $18.9 million of cash at the end of November 2025 and enough runway into the second quarter of 2027. That does not automatically make the mark unreliable. It does mean the largest asset in the portfolio still depends partly on management data that is not fully disclosed in the main public narrative.

TripleW presents the inverse picture. There is more operating color, but still no mature economics. The company ended 2025 with only about EUR 310 thousand of revenue at the subsidiary level, with EUR 3.8 million of cash and a monthly burn rate of EUR 350 thousand. It has approvals and grant support, including grants approved in 2024 totaling about NIS 68 million, of which NIS 34 million had already been received, a EUR 13.7 million CBE JU grant of which EUR 4.8 million had been received, and an additional EUR 9.45 million CINEA grant that had not yet been drawn. That clearly strengthens the story. But the company itself still estimates it will need more investment in the second half of 2026. So here too the path is not commercialization that eliminates funding needs, but commercialization that still requires funding.

Pitolon has the sharpest mix of upside and risk. On one hand, it had no revenue in 2024 or 2025, and the company itself projects roughly $10 million of revenue in 2026, a number the annual package explicitly says is not audited. At the end of 2025 Pitolon had $4.4 million of cash, a monthly burn of $480 thousand, and annual R&D spending of $3.5 million. On the other hand, it completed a roughly $6.6 million SAFE round in September 2025 with new investors including Grupo Bimbo and Colorcon, received FDA approval after the balance sheet date, and is examining a strategic raise. That makes Pitolon both the holding with the clearest reset potential and the holding that is still far from a fully public revenue proof point.

Cash Flow, Capital Structure And Funding

This is not a story of heavy bank debt or tight covenants. There are no such pressures here. Total liabilities at the end of 2025 were only NIS 1.259 million, of which NIS 836 thousand were current. The real problem is different: this is a partnership financing a private portfolio, so the right question is how much real cash flexibility remains once the accounting optics are stripped away.

Using an all-in cash-flexibility frame, end-2025 looks less comfortable than the equity figure suggests. The partnership held NIS 1.483 million of cash and cash equivalents. It also held NIS 6.893 million of tradable securities at fair value, mainly high-grade corporate bonds. That is an extra liquidity layer, but not the same thing as bank cash. During 2025 Millennium used NIS 2.523 million in operating activity and another NIS 2.714 million in investing activity. In total, NIS 5.237 million of cash was consumed. No financing cash came in during 2025 itself.

If cash and tradable securities are combined, the liquid layer before the post-balance-sheet raise stood at about NIS 8.376 million. That equals roughly 1.6 years of 2025 cash burn, and only if no unusually large follow-on investments are needed. After the rights offering, the time cushion improved materially, but even that has to be read correctly. The offering bought time. It did not make the partnership self-funding.

Management Fees And Dilution Are Already Part Of The Story

One seemingly small detail matters here. Under the partnership agreement, the general partner is entitled to a monthly management fee of $25 thousand, with an exchange-rate floor of NIS 3.5 per dollar. In June 2025, unitholders approved a deferral of $5 thousand per month out of that fee until the first realization of a portfolio holding. That modestly eases near-term cash use. But the very existence of that deferral says something about the current stage of the vehicle: even the public-platform cost layer is being stretched toward a realization event that still has not happened.

The complexity does not end there. Starting in 2026, the general partner can reverse the deferral prospectively if the partnership is not approved to continue investing in new portfolio companies, and it can ask to exchange the deferred amounts for newly issued units based on a 45-day average trading price. In other words, part of the cash relief can later turn into equity issuance.

The rights offering itself has already changed the capital structure. As of the report date, Millennium had 18,018,433 participation units listed for trading and another 7,621,537 warrants in Series 2, each exercisable at NIS 1 until September 3, 2026. The meaning is simple: even after the capital raise has already been completed, the market still carries another potential dilution layer on the screen.

Outlook

This is the heart of the story, because 2026 will not be judged mainly by the next accounting loss. It will be judged by whether one of the major assets starts turning book value into something that looks like realizable value.

The first finding: 2026 looks more like a proof and bridge year than a breakout year. The post-balance-sheet raise and the liquid-securities layer bought time, but they did not solve the need for further financing inside the private portfolio.

The second finding: Pitolon is currently the only holding with a near-term regulatory and commercial thread that can change both the valuation narrative and the market's reading of Millennium. But that same Pitolon still expects to need funding in 2026.

The third finding: Tipa and TripleW support most of the book value, yet both still sit in a zone where success is measured first by commercialization and financing durability, and only later by cash that can actually move up to the listed partnership.

The fourth finding: what changed in 2025 is not that risk disappeared. It is that the center of gravity shifted. There is less fear of an immediate broad portfolio collapse, and more concern that Millennium may spend a long time carrying high accounting value that remains hard to access.

What Must Happen In Pitolon

If investors are looking for the event that can change the reading of Millennium over the near term, it is Pitolon. Not because it is already the biggest asset, but because it may be the first one to deliver a strong outside validation. FDA approval for Beetroot Red is not an internal mark and not a secondary-market price. It is a regulatory milestone. If that becomes actual supply, and if the strategic-investor process closes at a stronger valuation, Millennium will get its first sharp external proof point on one of its three core holdings.

But this still needs to be kept in proportion. Pitolon itself says it had no revenue in 2024 and 2025, that its 2026 revenue target is about $10 million, and that it ended 2025 with $4.4 million of cash against a $480 thousand monthly burn. That is exactly what a proof year looks like. If first sales and a strategic round both materialize, the read on Millennium improves. If not, the partnership will still own a promising asset, but not yet a liquid one.

What Needs To Hold At Tipa And TripleW

Tipa is now the largest holding, so it does not need to produce an exit in order to carry the thesis. It mainly needs to avoid disappointment. The Dutch acquisitions, the new product range and the message that no near-term capital is needed are all meant to show that Tipa can keep moving without opening another funding hole. If it turns out that more capital is needed earlier than expected, or that the European commercial response is weaker than hoped, that will matter precisely because Tipa is now the largest book-value anchor.

TripleW faces a slightly different hurdle. Here the issue is not just preserving value, but showing that the move from lab and grant support toward plant build-out and revenue is progressing at a real pace. About EUR 310 thousand of 2025 revenue is a start, not proof. On the other hand, the combination of grants, the Antwerp site, the 6,000-ton LOI and regulatory progress does build a tangible story. So 2026 at TripleW will be a test of whether the company is moving from “many approvals” to “more commercial activity and less dependence on funding support”.

What Kind Of Year Is 2026

That is why 2026 looks like a proof and bridge year. It is not a reset year, because the portfolio still carries real value. It is also not a breakout year, because no single holding has yet shown broad commercialization or a clear realization path. For the reading to improve over the next 2 to 4 quarters, at least one of the following needs to happen: Pitolon closes a strategic round or starts selling, Tipa shows commercial resilience without another funding ask, TripleW demonstrates that grants and industrial agreements are turning into actual industrial execution, and Millennium itself avoids a quick return to the market for more time.

There is also a point the market may miss on first read. A meaningful part of the 2025 hit came from currency, not from pure quality erosion. But that is still only partial comfort. If the value is not realized, it does not matter much whether it eroded through FX or through an internal mark-down. In both cases, unitholders still hold value that has not reached them.

Risks

Concentration And Valuation Risk

The first risk is concentration. The four largest holdings account for about 97.4% of the private portfolio. The three material holdings alone account for about 73.5% of total assets. The meaning is straightforward: one major disappointment in one of those three assets can quickly hit equity again.

There is also a quality risk beside the concentration. The portfolio-company descriptions are explicitly based on information the holdings themselves provided to Millennium. The valuation review for Tipa and TripleW relies on management data and future assumptions, and the valuer explicitly says it did not independently verify all of the information. That does not mean the marks are wrong. It does mean they should be treated like private-market value, not like cash.

Funding And Dilution Risk

The second risk is funding risk, not in a bank-debt sense but in a capital-markets sense. Several of the key portfolio companies are still funding-dependent. Millennium itself also relied on a rights offering after the balance sheet date. As long as the public market keeps valuing the partnership at a deep discount and on very low turnover, any future raise can come at a heavy equity cost.

Legal And Governance Overhang

The third risk is legal and governance-related. There is a motion to certify a class action and related claim whose alleged damage is estimated at about NIS 107.7 million, focused on dilutive capital raises and conduct allegedly contrary to the partnership's purpose. Millennium's position is that the odds of dismissal, and of no material financial outcome, are higher than the odds of a material liability. That does not create a measured debt right now, but it does leave a layer of noise hanging over the stock and reinforces the market's caution.

Beyond that, the annual report itself says the security and economic environment in Israel is hurting foreign investors' willingness to fund Israeli companies, and in some cases also the ability of portfolio companies to raise money. For a vehicle whose core engine is follow-on funding and international commercialization, that is not just macro background. It is part of the thesis.

Conclusions

Millennium Food-Tech at the end of 2025 is not an empty shell, but it is also not a story where equity is already on its way to unitholders. What supports the thesis today is that the portfolio has not been wiped out, the three core holdings still carry most of the value, and Pitolon has already delivered a post-balance-sheet regulatory event that can become a commercial event. What blocks the thesis is that this value remains private, concentrated and funding-dependent. What will drive the market reading over the short to medium term is not another accounting mark by itself, but whether one core holding can actually produce strong outside validation.

Current thesis in one line: Millennium's book value is still there, but the gap to the market will not close until the partnership shows that at least one major asset can move from internal funding and fair-value marks toward commercialization or high-quality external financing.

What changed versus the broader historical reading of Millennium is that the story is now much less about a wide portfolio and much more about concentration. Several holdings have already been written down or weakened, and the real question now sits on Tipa, TripleW and Pitolon. The strongest counter-thesis is that the market is being too conservative, because not all of 2025's damage reflects real economic deterioration, part of it was currency, and Millennium now has more time after the rights offering. What could change the market's reading in the near term is mainly an external validation event at Pitolon, or proof that Tipa and TripleW are not heading toward another early funding need.

Why does this matter? Because this is a question of value quality, not just value size. If Millennium can show that its private marks are starting to turn into commercialization, better outside financing, or real cash, the read on the entire partnership can change. If not, the discount can remain in place even against a high reported equity figure.

What has to happen over the next 2 to 4 quarters for the thesis to strengthen is fairly clear: Pitolon needs to turn approval and negotiations into sales or a high-quality outside round, Tipa needs to hold its progress without asking for new capital, TripleW needs to show that grants and agreements are progressing toward real industrial activity, and Millennium itself needs to avoid returning too quickly to the equity market. What would weaken the thesis? Another round of dilution before any of those triggers materializes, or evidence that the core book value starts eroding again without strong outside confirmation.